BZYR.US Burzynski Research

Healthcare Biotechnology USA Stocks
0.0002 USD
Close of Oct 12, 2026
0.0002 0.0470
Market cap
USD 26.3K
P/E
-
P/B
2,190.81x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Nov 2025.

Is BZYR.US undervalued?

Graham number

The Graham number of Burzynski Research cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Burzynski Research fundamental analysis

No fundamental analysis for Burzynski Research yet.

Burzynski Research stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Burzynski Research

Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.

Full company profile